You can accurately test for Neisseria gonorrheae (NG) and Chlamydia trachomatis (CT) using the same liquid Pap specimens collected for cervical cytology, researchers from University of Oklahoma college of Medicine in Tulsa have concluded.
You can accurately test for Neisseria gonorrheae (NG) and Chlamydia trachomatis (CT) using the same liquid Pap specimens collected for cervical cytology, researchers from University of Oklahoma college of Medicine in Tulsa have concluded. They undertook a study involving these two other STDs after two liquid-based cytology tests-ThinPrep (Cytyc Corp.) and SurePath (TriPath Imaging) had already shown the ability to retrieve additional test results for the human papillomavirus virus from fluid remaining after Pap smear preparation.
With the FDA approval of ThinPrep for the new indication of using remaining test fluid to detect gonorrhea and chlamydia, study researchers set out to assess the clinical usefulness of SurePath for the simultaneous preparation of the Pap smear and screening for NG and CT using the transcription mediated nucleic acid amplification tests (NAAT), APTIMA Combo 2 (AC2), APTIMA GC and CT assays.
Investigators collected separate cervical samples from 1,615 patients (from six states) for liquid Pap cytologic assessment using SurePath and for STD testing using the amplification assays mentioned above. They then tested an aliquot from the separate samples for NG and CT at the same time and assessed the results for sensitivity and specificity.
Investigators further concluded that a single collected specimen for cervical cytology and analysis for these two STDS as well as HPV may potentially lead to an easier and cheaper way to detect and treat all three.
Martens M, Hook EW III, Freund G, et al. Efficacy of screening for Neisseria gonorrheae and Chlamydia trachomatis from liquid Pap tests. Obstet Gynecol. 2006;107(4 suppl):55S.
Unlocking HPV prevention: Insights from 2022 data on vaccination trends
May 14th 2024Explore the latest findings revealing vaccination rates among children aged 9 to 17 years, uncovering demographic disparities and highlighting the crucial role of vaccination in combating human papillomavirus infections and related health risks.
Read More
Prenatal cannabis and nicotine use linked to adverse pregnancy outcomes
May 14th 2024A recent study highlights the heightened risks of maternal and neonatal morbidity and mortality associated with combined cannabis and nicotine use during pregnancy, urging further investigation into their impact on short- and long-term outcomes.
Read More
Understanding pediatric STIs: Trends, management, and more
May 10th 2024Dive into the rising prevalence of sexually transmitted infections among adolescents and young adults, exploring educational gaps, vaccination rates, and the imperative need for open conversations between patients and health care providers to combat stigma and enhance preventive care.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More